Shandong Boan Biotechnology Future Growth
Future criteria checks 2/6
Shandong Boan Biotechnology is forecast to grow revenue at 29% per annum. EPS is expected to decline by 15.9% per annum.
Key information
n/a
Earnings growth rate
-15.9%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 29.0% |
| Future return on equity | -8.8% |
| Analyst coverage | Low |
| Last updated | 22 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,399 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 930 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 723 | N/A | N/A | N/A | 1 |
| 6/30/2024 | 720 | 62 | -442 | -40 | N/A |
| 3/31/2024 | 669 | -29 | -377 | -29 | N/A |
| 12/31/2023 | 618 | -119 | -313 | -19 | N/A |
| 9/30/2023 | 587 | -209 | -338 | -67 | N/A |
| 6/30/2023 | 557 | -298 | -363 | -116 | N/A |
| 3/31/2023 | 536 | -315 | -386 | -159 | N/A |
| 12/31/2022 | 516 | -332 | -408 | -202 | N/A |
| 9/30/2022 | 442 | -291 | -448 | -205 | N/A |
| 6/30/2022 | 367 | -251 | -487 | -209 | N/A |
| 3/31/2022 | 263 | -238 | -537 | -228 | N/A |
| 12/31/2021 | 159 | -225 | -588 | -246 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if UJ9's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if UJ9's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if UJ9's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: UJ9's revenue (29% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: UJ9's revenue (29% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: UJ9 is forecast to be unprofitable in 3 years.